E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Critical Limb Ischemia Rutherford clas 4-6 |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the trial is to compare the effects of treatment with ASCT01 in patients with an endstage Critical Limb Ischemia vs a placebo therapy. |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety profile of ASCT01 during the study To document other efficacy parameters such as: a.major Amputations and wound healing Changes in: b. Ankle-Brachial Index (AB-index) c. Transcutaneous oxygen pressure (Tcp02) d. Quality of life (EQ-5D Questionnaire) e. Rutherford grade and stage f. Angiography g. Walking index in speed and distance without and with pain h. Wound healing |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
A sub study is planned in order to further characterize ASCT01 and to investigate the possible correlation between the composition of ASCT01 and the biological effects of the product. The sub study will only be performed on ASCT01 samples left over after injection of ASCT01 containing at least 2 million CD34+, or on ASCT01 prepared from patients randomized in the placebo arm. The aim of the complementary characterization is to gain a better understanding on qualitative and quantitative entities present in ASCT01. At the end of the study (after the unblinding) the correlation between the composition of ASCT01 and the biological effect of the product will be investigated. |
|
E.3 | Principal inclusion criteria |
1. Patients in the age group of 18-75 yrs. 2. Established CLI (confirmed by Rutherford 4 to 6 or Fontaine III-IV to the recommendations of the TASC) with infra-inguinal arterial occlusive disease 3. Ankle Brachial Pressure Index (ABPI) ≤ 0.6 or the absolute ankle blood pressure < 60 mm Hg or TcPO2 <20 mmHg without tissue loss or TcPO2 <40 mmHg if there is tissue loss. 4. No surgical or interventional option for revascularization and no response to best standard care delivered as confirmed by a vascular surgeon. 5. No immediate life-threatening complication from CLI which would demand immediate amputation. 6. Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits. 7. Coagulation status aPTT within normal limits 8. Sufficient number of stem cells isolated from bone marrow (> 2 million CD34+). 9. Viability of isolated stem cells > 90%.
|
|
E.4 | Principal exclusion criteria |
1. Acute life threatening complication of limb ischemia with the need for immediate limb amputation to avoid death or clinical deterioration 2. Patients with documented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 6 months. 3. Patients with a history of severe alcohol or drug abuse within 3 months of screening. 4. Known bone marrow diseases which preclude transplantation. 5. End-stage renal failure on regular dialysis treatment 6. Patients already enrolled in another investigational drug trial or completed within 3 months. 7. Pregnancy. 8. Patients tested positive for HIV 1, HCV, and/or HBV
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome variable is a major amputation (above the ankle) of the affected limb after 3 months or an unchanged critical limb ischemia of the affected limb after 3 months defined as less than 15% change in tcPO2 or ABI or absolute ankle pressure. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |